Ianalumab for MMN — Evidence & Clinical Trials

Overview

Treatment Details

Mechanism of Action

An investigational monoclonal antibody with a dual mechanism: it blocks the BAFF receptor (BAFF-R) on B cells, similar in concept to belimumab's BLyS-blocking approach, while also directly depleting B cells via antibody-dependent cellular cytotoxicity — combining two complementary B-cell-targeting strategies in one molecule. Being evaluated in Phase 3 SIRIUS-SLE 1 and SIRIUS-SLE 2 trials, with data expected in 2027.

Dosing Notes

Investigational; subcutaneous injection, dosing under evaluation in Phase 3 trials.

Treatment Type

pharmaceutical

Clinical Evidence

What the Evidence Shows

Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.

High: Supported by multiple robust studies or regulatory approval

Moderate: Supported by limited controlled studies or consistent case series

Low: Based on case reports, expert opinion, or early-phase data only

Low ConfidenceBased on case reports, expert opinion, or early-phase data only

Ianalumab is in Phase III evaluation (SIRIUS-SLE 1 and 2) combining BAFF-R blockade with direct B-cell depletion; per Novartis' Q3 2025 update, Phase III data are expected in 2027, with regulatory filings anticipated in 2028 or later.

Verified Jul 2026

Institutional Research

Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape

Published July 2026

View source ↗

Clinical Trials

Linked Trials2 trials

NCT05639114 ↗ clinicaltrials.gov

SRI-4 response rate at Week 52 with ianalumab versus placebo on background standard of care

Target enrollment: 450 participants

Phase 3

Recruiting